ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Phase 2
200
about 4.8 years
18+
Male only
16 sites in CA, CO, FL +10
What this study is about
Researchers are testing whether ZEN003694, taken with enzalutamide, is more effective than enzalutamide alone for men whose prostate cancer has returned after treatment with abiraterone. The trial will enroll approximately 200 men who have progressed on abiraterone and are considered castration-resistant. Patients will be divided into two groups: those who did not respond well to abiraterone, or those who responded well to abiraterone.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Enzalutamide
- 2.Take ZEN003694
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
enzalutamide
oral (Oral Tablet)
Primary: Cohort A: Radiographic progression-free survival (rPFS) by BICR
Secondary: Cohort A + B: Overall survival (OS), Cohort A + B: PSA50 response rate, Cohort A + B: Progression-free survival (PFS) by investigator assessment, Cohort A + B: Radiographic progression-free survival (rPFS) by investigator assessment, Cohort A: Overall survival (OS), Cohort A: PSA50 response rate, Cohort A: Progression-free survival (PFS) by investigator assessment, Cohort A: Radiographic progression-free survival (rPFS) by investigator assessment
Oncology